NYSE · CIK 0001935979
BHVN Biohaven Ltd.
Insider trading from SEC Form 4. Last filing 24 d ago. Close $12.08 on Oct 9, 2026, +55% from the 52-week low and -33% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
BHVNOct 9, 2026 · close 12.08
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Biohaven Ltd., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 45Moderate | buy | John W Childs director | $996k | 32,700 | +1% | - | |
| 40Moderate | buy | John W Childs director | $1.0M | 29,000 | +1% | - |
Transactions
The last 31 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Kimberly Gentile SVP, Clinical Operations | AGrant or award Stock Options (Right to buy)derivativeindirect: By Son | +1,000 | $0.00 | $0 | 1,000 | 24 d ago |
| Mar 4, 2025 | John W Childs director | POpen-market purchase Common Sharesindirect: By John W Childs 2013 Revocable Trust | +25,000 | $30.39 | $760k | 2,320,571 | Mar 5, 2025 |
| Mar 4, 2025 | John W Childs director | POpen-market purchase Common Sharesindirect: By 2007 Charitable Remainder Trust | +3,400 | $30.73 | $104k | 24,452 | Mar 5, 2025 |
| Mar 4, 2025 | John W Childs director | POpen-market purchase Common Sharesindirect: By 2013 Charitable Remainder Trust | +3,400 | $30.73 | $104k | 76,570 | Mar 5, 2025 |
| Mar 4, 2025 | John W Childs director | POpen-market purchase Common Sharesindirect: By 1994 Charitable Remainder Trust | +900 | $30.73 | $28k | 25,291 | Mar 5, 2025 |
| Jan 5, 2025 | George C. Clark VP, Chief Accounting Officer | MOption exercise Common Shares | +2,500 | $0.00 | $0 | 66,168 | Jan 7, 2025 |
| Jan 5, 2025 | Bruce Car Chief Scientific Officer | MOption exercise Common Shares | +4,750 | $0.00 | $0 | 7,133 | Jan 7, 2025 |
| Jan 5, 2025 | Kimberly Gentile SVP, Clinical Operations | MOption exercise Common Shares | +3,750 | $0.00 | $0 | 99,719 | Jan 7, 2025 |
| Jan 5, 2025 | Matthew Buten Chief Financial Officer | MOption exercise Common Shares | +4,250 | $0.00 | $0 | 196,013 | Jan 7, 2025 |
| Jan 5, 2025 | Vlad Coric Chief Executive Officer | MOption exercise Common Shares | +14,250 | $0.00 | $0 | 1,803,409 | Jan 7, 2025 |
| Jan 5, 2025 | Matthew Buten Chief Financial Officer | FTax withholding Common Shares | -2,561 | $38.64 | $99k | 193,452 | Jan 7, 2025 |
| Jan 5, 2025 | Kimberly Gentile SVP, Clinical Operations | FTax withholding Common Shares | -1,956 | $38.64 | $76k | 97,763 | Jan 7, 2025 |
| Jan 5, 2025 | George C. Clark VP, Chief Accounting Officer | FTax withholding Common Shares | -1,117 | $38.64 | $43k | 65,051 | Jan 7, 2025 |
| Jan 5, 2025 | Vlad Coric Chief Executive Officer | FTax withholding Common Shares | -6,805 | $38.64 | $263k | 1,796,604 | Jan 7, 2025 |
| Jan 5, 2025 | Bruce Car Chief Scientific Officer | FTax withholding Common Shares | -2,331 | $38.64 | $90k | 4,802 | Jan 7, 2025 |
| Jan 5, 2025 | Matthew Buten Chief Financial Officer | AGrant or award Stock Options (Right to buy)derivative | +104,000 | $0.00 | $0 | 104,000 | Jan 7, 2025 |
| Jan 5, 2025 | Kimberly Gentile SVP, Clinical Operations | AGrant or award Stock Options (Right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 7, 2025 |
| Jan 5, 2025 | George C. Clark VP, Chief Accounting Officer | AGrant or award Stock Options (Right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jan 7, 2025 |
| Jan 5, 2025 | Kimberly Gentile SVP, Clinical Operations | AGrant or award Restricted Share Unit Awardderivative | +15,000 | $0.00 | $0 | 15,000 | Jan 7, 2025 |
| Jan 5, 2025 | Bruce Car Chief Scientific Officer | AGrant or award Stock Options (Right to buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jan 7, 2025 |
| Jan 5, 2025 | Matthew Buten Chief Financial Officer | AGrant or award Restricted Share Unit Awardderivative | +17,000 | $0.00 | $0 | 17,000 | Jan 7, 2025 |
| Jan 5, 2025 | George C. Clark VP, Chief Accounting Officer | AGrant or award Restricted Share Unit Awardderivative | +10,000 | $0.00 | $0 | 10,000 | Jan 7, 2025 |
| Jan 5, 2025 | Matthew Buten Chief Financial Officer | MOption exercise Restricted Share Unit Awardderivative | -4,250 | $0.00 | $0 | 12,750 | Jan 7, 2025 |
| Jan 5, 2025 | Kimberly Gentile SVP, Clinical Operations | MOption exercise Restricted Share Unit Awardderivative | -3,750 | $0.00 | $0 | 11,250 | Jan 7, 2025 |
| Jan 5, 2025 | Bruce Car Chief Scientific Officer | AGrant or award Restricted Share Unit Awardderivative | +19,000 | $0.00 | $0 | 19,000 | Jan 7, 2025 |
| Jan 5, 2025 | George C. Clark VP, Chief Accounting Officer | MOption exercise Restricted Share Unit Awardderivative | -2,500 | $0.00 | $0 | 7,500 | Jan 7, 2025 |
| Jan 5, 2025 | Vlad Coric Chief Executive Officer | AGrant or award Stock Options (Right to buy)derivative | +343,000 | $0.00 | $0 | 343,000 | Jan 7, 2025 |
| Jan 5, 2025 | Bruce Car Chief Scientific Officer | MOption exercise Restricted Share Unit Awardderivative | -4,750 | $0.00 | $0 | 14,250 | Jan 7, 2025 |
| Jan 5, 2025 | Vlad Coric Chief Executive Officer | AGrant or award Restricted Share Unit Awardderivative | +57,000 | $0.00 | $0 | 57,000 | Jan 7, 2025 |
| Jan 5, 2025 | Vlad Coric Chief Executive Officer | MOption exercise Restricted Share Unit Awardderivative | -14,250 | $0.00 | $0 | 42,750 | Jan 7, 2025 |
| Dec 30, 2024 | John W Childs director | POpen-market purchase Common Sharesindirect: By John W Childs 2013 Revocable Trust | +29,000 | $35.94 | $1.0M | 2,368,741 | Dec 31, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Matthew ButenChief Financial Officer
- John W Childsdirector
- Bruce CarChief Scientific Officer
- George C. ClarkVP, Chief Accounting Officer
- Vlad CoricChief Executive Officer
- Kimberly GentileSVP, Clinical Operations
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.